HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
Liquid biopsies have emerged as a transformative tool in cancer research, offering a less invasive alternative to traditional tissue biopsies for detecting cancer-related genetic mutations. Liquid biopsies analyze blood, urine, or other bodily fluids for cancer biomarkers, such as circulating tumor DNA (ctDNA), which can provide early signs of cancer. This technology has revolutionized cancer monitoring by enabling doctors to track a patient’s response to treatment and detect recurrence before clinical symptoms appear. Liquid biopsies are also being explored for their potential to detect minimal residual disease, providing valuable insights into the effectiveness of treatments and guiding personalized care strategies for patients.
